To demonstrate the feasibility of metal-based conjugates, we firstdeveloped a conjugate targeting the AFF4–CCTN1 PPI, a componentwithin the super elongation complex (SEC).This PPI drives oncogenictranscription in TNBC by activating MYC, a key regulator of proliferation,metastasis, and cancer stem cell (CSC) phenotypes. Dysregulation of this PPI promotes tumor aggressivenessand resistance to conventional therapies, highlighting CCNT1 as acritical therapeutic target. However,the lack of selective inhibitors for this interaction has hinderedclinical progress. The gene discussed is MYC; the disease is neoplasm.